{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:42:51Z","timestamp":1792395771419,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhepr.2026.102068","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:13:39Z","timestamp":1792250019000},"page":"102068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 2 study of fazpilodemab, a FGFR1\/Klotho\u03b2 agonist, in metabolic dysfunction-associated steatohepatitis (MASH)"],"prefix":"10.1016","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-4309","authenticated-orcid":false,"given":"Jill","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-9231","authenticated-orcid":false,"given":"Chin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2026.102068_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102068_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102068_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102068_bib4","unstructured":"Rezdiffra (resmetirom) tablets. Prescribing Information. Madrigal Pharmaceuticals Inc.; 2024."},{"issue":"21","key":"10.1016\/j.jhepr.2026.102068_bib5","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102068_bib6","unstructured":"Wegovy (semaglutide) injection. Prescribing Information. Novo Nordisk Inc.; 2025"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102068_bib7","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhepr.2026.102068_bib8","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.cgh.2024.10.025","article-title":"Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study","volume":"23","author":"Lassailly","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102068_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"issue":"162","key":"10.1016\/j.jhepr.2026.102068_bib10","doi-asserted-by":"crossref","first-page":"162ra153","DOI":"10.1126\/scitranslmed.3004690","article-title":"Treating diabetes and obesity with an FGF21-mimetic antibody activating the \u03b2Klotho\/FGFR1c receptor complex","volume":"4","author":"Foltz","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jhepr.2026.102068_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1\/\u03b2Klotho Complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102068_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial","volume":"78","author":"Wong","year":"2023","journal-title":"Hepatology"},{"issue":"46","key":"10.1016\/j.jhepr.2026.102068_bib13","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc Natl Acad Sc"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102068_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:10:49Z","timestamp":1792393849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"alternative-id":["S2589555926003393"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102068","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 study of fazpilodemab, a FGFR1\/Klotho\u03b2 agonist, in metabolic dysfunction-associated steatohepatitis (MASH)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Genentech, Inc. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102068"}}